Urology
Volume 76, Issue 2 , Pages 430-434 , August 2010

Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy

  • Michael M. Vickers

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • ,
  • Toni K. Choueiri

      Affiliations

    • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Miranda Rogers

      Affiliations

    • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Andrew Percy

      Affiliations

    • Department of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Daygen Finch

      Affiliations

    • Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Ivan Zama

      Affiliations

    • Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
    • ,
  • Tina Cheng

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • ,
  • Scott North

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Jennifer J. Knox

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Christian Kollmannsberger

      Affiliations

    • Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • David F. McDermott

      Affiliations

    • Department of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Brian I. Rini

      Affiliations

    • Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
    • ,
  • Daniel Y. Heng

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • Corresponding Author InformationReprint requests: Daniel Y. C. Heng, M.D., M.P.H., F.R.C.P.C., Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331–29th Street NW, Calgary, Alberta, Canada T2N 4N2

Received 30 November 2009 ,Accepted 5 December 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Conflicts of interests: Toni K. Choueiri, Honoraria: Novartis, Abbott, GSK, Genentech, Consultant/Advisory role: Bayer, Onyx, Pfizer; Scott North, Honoraria: Pfizer, Bayer, Wyeth; Brian I. Rini, Honoraria: Wyeth, Pfizer, Genentech, Bayer, Onyx, Consultant/Advisory role: Pfizer, Onyx, Wyeth, Bayer, Genentech; Daniel Y. Heng, Honoraria: Bayer, Wyeth, Pfizer. Michael M. Vickers, Miranda Rogers, Andrew Percy, Daygen Finch, Ivan Zama, Tina Cheng, Jennifer J. Knox, Christian Kollmannsberger, and David F. McDermott had no conflicts of interest.

PII: S0090-4295(09)03118-5

doi: 10.1016/j.urology.2009.12.031

Urology
Volume 76, Issue 2 , Pages 430-434 , August 2010

Article Tools

* Image Usage & Resolution